MediWound Ltd. Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual Form 20-F, not a standalone fourth-quarter report; quarterly Q4 figures are not separately presented in the supplied text. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars.
Business Context
MediWound is an Israeli biopharmaceutical company developing, manufacturing and commercializing enzymatic therapies for burn care, chronic wounds and tissue repair. Its marketed product, NexoBrid, is approved in more than 40 countries for eschar removal in severe thermal burns. EscharEx is a Phase III-ready candidate for chronic and hard-to-heal wounds, while MW005 is an earlier-stage candidate for basal cell carcinoma.
- NexoBrid launched in the United States through Vericel in September 2023, in Japan during the third quarter, and in India during the fourth quarter.
- The European Commission approved NexoBrid for burn eschar removal in patients of all ages in December 2023.
- The U.S. FDA accepted the pediatric supplemental BLA for review in September 2023, with a decision expected in the second half of 2024.
- As of December 31, 2023, the company had 9,221,764 ordinary shares outstanding and 100 employees.
Financial Performance and Position
| U.S. dollars in millions, except per-share data | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $18.7 | $26.5 | Down 29% |
| Gross profit | $3.6 | $13.2 | Down 73% |
| Gross margin | 19.2% | 49.7% | Down 30.5 percentage points |
| Operating loss | $(15.3) | $(8.3) | Loss increased |
| Net loss | $(6.7) | $(19.6) | Loss narrowed |
| Basic and diluted loss per share | $(0.75) | $(3.93) | Improved |
| Net cash used in operating activities | $(10.5) | $(11.9) | Improved |
| Net cash used in investing activities | $(34.3) | $(0.5) | Higher investment |
| Net cash provided by financing activities | $22.9 | $35.8 | Lower |
- Product sales increased 17% to $6.3 million from $5.3 million, primarily due to new customers.
- Development-services revenue declined 5% to $12.3 million, mainly due to BARDA-related activity.
- License and royalty revenue fell to $0.2 million from $8.2 million because 2022 included Vericel’s $7.5 million BLA approval milestone.
- Cost of revenues increased to $15.1 million from $13.3 million, and represented 81% of revenue versus 50% in 2022. Product cost represented approximately 79% of product revenue.
- Research and development expense declined 27% to $7.5 million after completion of the EscharEx Phase II study. Selling and marketing expense increased 30% to $4.8 million.
- Financial income was $10.7 million, including an $8.3 million favorable warrant revaluation and $2.3 million of interest income. This compared with $11.6 million of financial expense in 2022, largely reflecting the prior-year warrant revaluation.
- Cash, cash equivalents, short-term and restricted bank deposits totaled $41.7 million at year-end, including $11.9 million of cash and cash equivalents and $29.8 million of short-term and restricted deposits.
- Total assets were $66.5 million, total liabilities were $34.9 million and shareholders’ equity was $31.6 million.
- The company reported no long-term debt exposure in its market-risk discussion, but had $6.4 million of non-current lease liabilities, $7.7 million of IIA grant liabilities, $2.3 million of Teva liabilities and $7.3 million of warrant liabilities.
Material Changes Versus 2022
- Revenue declined primarily because the $7.5 million Vericel BLA milestone recognized in 2022 did not recur.
- Product revenue grew, but the revenue mix shifted toward lower-margin product and development-service revenue, significantly reducing gross margin.
- Operating loss widened despite lower research and development spending, reflecting the revenue decline and higher selling and marketing costs.
- Net loss improved substantially because of favorable non-cash warrant revaluation and higher interest income.
- Operating cash burn improved modestly, while investing cash outflows increased sharply due to short-term deposit investments and manufacturing-capacity expansion.
- In February 2023, the company issued 1,964,286 ordinary shares at $14 per share, generating gross proceeds of approximately $27.5 million and net proceeds of approximately $25.5 million.
- Property, plant and equipment increased to $9.2 million from $2.4 million, principally reflecting manufacturing scale-up investment.
- Issued and outstanding shares increased from 7,240,020 at year-end 2022 to 9,221,764 at year-end 2023, creating dilution for existing shareholders.
Guidance, Outlook and Management Commentary
- The company expects continued operating losses and significant expenses as it advances EscharEx, MW005 and other pipeline programs, expands NexoBrid commercialization and increases manufacturing capacity.
- Management expects existing cash, cash equivalents, short-term deposits and restricted deposits to fund operations and capital expenditures for at least twelve months from the financial-statement issuance date. The filing also states that additional financing may be required sooner if spending or market conditions differ from expectations.
- A new GMP-compliant NexoBrid manufacturing facility is projected to be completed by mid-2024, with full-scale manufacturing expected in 2025 and an estimated investment of approximately $12.7 million. The facility is expected to increase capacity up to sixfold.
- The EscharEx Phase III study is expected to begin in the second half of 2024, subject to final protocol submission and regulatory requirements. The planned study includes 216 patients at approximately 40 sites.
- The company is pursuing an extension of the First BARDA Contract, currently scheduled to run through September 2024. As of year-end 2023, approximately $88.3 million had been received for development activities and $16.5 million for emergency-preparedness procurement under that contract.
- DOD/MTEC awarded approximately $10.3 million during 2023 for development of a temperature-stable NexoBrid formulation. Government contracts may be terminated at the agencies’ discretion.
- Management identified supply-chain disruption, inflation, interest rates, foreign exchange and recessionary conditions as potential pressures. Approximately 45% of operating expenses were denominated in Israeli shekels in 2023, and the company does not currently hedge this exposure.
Key Risks, Contingencies and Unusual Items
- The business remains dependent on NexoBrid commercialization, particularly the performance of Vericel in North America, BARDA procurement and market adoption in international markets.
- Global demand for NexoBrid exceeds current manufacturing capacity. Delays, cost overruns or regulatory issues affecting the expansion could constrain revenue growth.
- The company relies on a single supplier, Challenge Bioproducts Corporation, for bromelain SP, a key starting material. The supplier’s facilities are located in Taiwan, creating geopolitical and supply-continuity exposure.
- The company relies principally on a single manufacturing facility in Yavne, Israel. The Israel-Hamas war had no material effect on 2023 operations according to the filing, but the conflict could disrupt employees, facilities, logistics and production.
- EscharEx and MW005 remain subject to clinical, regulatory, manufacturing, reimbursement and market-acceptance risks; positive Phase II or Phase I/II results do not assure approval or commercialization.
- The company had an accumulated deficit of $174.8 million and a history of operating cash outflows. Future financing could involve equity dilution, debt obligations or unfavorable licensing arrangements.
- The $8.3 million favorable warrant revaluation in 2023 was non-cash and materially affected net loss relative to operating performance.
- The IIA grant liability was $7.8 million at year-end, based partly on estimates of future royalty-bearing sales and regulatory approvals. The auditor identified this valuation as a critical audit matter.
- The company remains subject to payments and royalties under agreements with Teva, the IIA and the licensor of certain intellectual property. Teva liabilities totaled approximately $4.4 million at year-end, including current and non-current amounts.
- The company reported effective disclosure controls and internal control over financial reporting, and KPMG issued an unqualified opinion on the financial statements and internal controls.
Investor Verification Checklist
- Verify quarterly revenue, gross margin and cash-burn trends because the 20-F provides annual results rather than separately reported Q4 figures.
- Track U.S. NexoBrid adoption, Vericel orders and royalties, BARDA procurement and the expected extension of the First BARDA Contract.
- Confirm completion, regulatory validation, cost and 2025 production start for the expanded Yavne manufacturing facility.
- Monitor the FDA decision on pediatric NexoBrid and the timing, enrollment and funding of the EscharEx Phase III program.
- Assess liquidity after manufacturing investments and operating cash burn, including the timing and terms of any additional capital raise.
- Review the effect of warrant liabilities, potential warrant exercises and outstanding options on future earnings volatility and dilution.
- Evaluate exposure to the sole bromelain SP supplier, Taiwan-related geopolitical risk and operational disruption in Israel.
- Reconcile reported cash and deposits of $41.7 million with restricted amounts, contractual obligations and expected capital expenditures.